Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer

American Journal of Gastroenterology

Volumn 112, Issue 1, 2017, Pages 37-53

  Robertson, Douglas J ^a,b   Lee, Jeffrey K ^c   Boland, C Richard ^d   Dominitz, Jason A ^e   Giardiello, Francis M ^f   Johnson, David A ^g   Kaltenbach, Tonya ^h   Lieberman, David ⁱ   Levin, Theodore R ^j   Rex, Douglas K ^k  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j KAISER PERMANENTE MEDICAL CENTER   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HEMOGLOBIN;

ADVANCED CANCER; CANCER PREVENTION; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL TUMOR; COMPARATIVE EFFECTIVENESS; DEGRADATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC VALUE; DIETARY INTAKE; DIGITAL RECTAL EXAMINATION; EVALUATION STUDY; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOCHEMISTRY; MEDICATION THERAPY MANAGEMENT; META ANALYSIS (TOPIC); OCCULT BLOOD; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEAT PROCEDURE; REVIEW; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; SUMMER; SYSTEMATIC REVIEW (TOPIC); ADENOMA; ADVISORY COMMITTEE; CARCINOMA; CHEMISTRY; COLORECTAL NEOPLASMS; CONSENSUS; EARLY CANCER DIAGNOSIS; FECES; UNITED STATES;

ADENOMA; ADVISORY COMMITTEES; CARCINOMA; COLONOSCOPY; COLORECTAL NEOPLASMS; CONSENSUS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FECES; HEMOGLOBINS; HUMANS; IMMUNOCHEMISTRY; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; UNITED STATES;

EID: 84991706700     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.492     Document Type: Review

References (120)

1. American Cancer Society. Cancer of the colon and rectum. CA Cancer J Clin 1980; 30: 208-15.
2. Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-7.
3. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-71.
4. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-71.
5. Shaukat A, Mongin SJ, Geisser MS et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013; 369: 1106-14.
6. Mandel JS, Church TR, Bond JH et al. The effect of fecal occultblood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-7.
7. Jaffe RM, Kasten B, Young DS et al. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med 1975; 83: 824-6.
8. Songster CL, Barrows GH, Jarrett DD. Immunochemical detection of fecal occult blood-the fecal smear punch-disc test: a new non-invasive screening test for colorectal cancer. Cancer 1980; 45: 1099-102.
9. Barrows GH, Burton RM, Jarrett DD et al. Immuno-chemical detection of human blood in feces. Am J Clin Pathol 1978; 69: 342-6.
10. Zorzi M, Fedeli U, Schievano E et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut 2015; 64: 784-90.
11. Chiang TH, Chuang SL, Chen SL et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoffconcentration in a nationwide colorectal cancer screening program. Gastroenterology 2014; 147: 1317-26.
12. Chiu HM, Chen SL, Yen AM et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer 2015; 121: 3221-9.
13. Centers for Disease Control and Prevention. Vital signs: colorectal cancer screening test use-United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 881-8.
14. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6.
15. Whitlock EP, Lin JS, Liles E et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638-58.
16. Lee JK, Liles EG, Bent S et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 2014; 160: 171.
17. Fraser CG, Allison JE, Halloran SP et al. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 2012; 104: 810-4.
18. Kahi CJ, Boland CR, Dominitz JA et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2016; 150: 758-768 e11.
19. Allison JE, Sakoda LC, Levin TR et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1462-70.
20. Allison JE, Tekawa IS, Ransom LJ et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 155-9.
21. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer 2013; 49: 3049-54.
22. Cheng TI, Wong JM, Hong CF et al. Colorectal cancer screening in asymptomaic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. J Formos Med Assoc 2002; 101: 685-90.
23. Chiang TH, Lee YC, Tu CH et al. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ 2011; 183: 1474-81.
24. Chiu HM, Lee YC, Tu CH et al. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol 2013; 11: 832-8. e1-2.
25. de Wijkerslooth TR, Stoop EM, Bossuyt PM et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol 2012; 107: 1570-8.
26. Itoh M, Takahashi K, Nishida H et al. Estimation of the optimal cut offpoint in a new immunological faecal occult blood test in a corporate colorectal cancer screening programme. J Med Screen 1996; 3: 66-71.
27. Launoy GD, Bertrand HJ, Berchi C et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 2005; 115: 493-6.
28. Levi Z, Birkenfeld S, Vilkin A et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer 2011; 128: 2415-24.
29. Levi Z, Rozen P, Hazazi R et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146: 244-55.
30. Morikawa T, Kato J, Yamaji Y et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-8.
31. Nakama H, Kamijo N, Abdul Fattah AS et al. Validity of immunological faecal occult blood screening for colorectal cancer: a follow up study. J Med Screen 1996; 3: 63-5.
32. Nakama H, Yamamoto M, Kamijo N et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999; 46: 228-31.
33. Park DI, Ryu S, Kim YH et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105: 2017-25.
34. Nakazato M, Yamano H-O, Matsushita H-O et al. Immunologic fecal occult blood test for colorectal cancer screening. Jpn Med Assoc J 2006; 49: 203.
35. Parra-Blanco A, Gimeno-Garcia AZ, Quintero E et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 2010; 45: 703-12.
36. Sohn DK, Jeong SY, Choi HS et al. Single immunochemical fecal occult blood test for detection of colorectal neoplasia. Cancer Res Treat 2005; 37: 20-23.
37. Imperiale TF, RansohoffDF, Itzkowitz SH et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370: 1287-97.
38. Hernandez V, Cubiella J, Gonzalez-Mao MC et al. Fecal immunochemical test accuracy in average-risk colorectal cancer screening. World J Gastroenterol 2014; 20: 1038-47.
39. Zubero MB, Arana-Arri E, Pijoan JI et al. Population-based colorectal cancer screening: comparison of two fecal occult blood test. Front Pharmacol 2014; 4: 175.
40. Graser A, Stieber P, Nagel D et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 2009; 58: 241-8.
41. Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 2010; 105: 682-90.
42. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 162-9.
43. Imperiale TF, Wagner DR, Lin CY et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343: 169-74.
44. Lieberman DA, Weiss DG, Bond JH et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-8.
45. Crotta S, Segnan N, Paganin S et al. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 2012; 10: 633-8.
46. Denters MJ, Deutekom M, Bossuyt PM et al. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology 2012; 142: 497-504.
47. Kapidzic A, Grobbee EJ, Hol L et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol 2014; 109: 1257-64.
48. McNamara D, Leen R, Seng-Lee C et al. Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght-Trinity College colorectal cancer screening programme with the faecal immunological test. Eur J Gastroenterol Hepatol 2014; 26: 1415-21.
49. Parente F, Boemo C, Ardizzoia A et al. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. Endoscopy 2013; 45: 27-34.
50. Stegeman I, van Doorn SC, Mundt MW et al. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening. Cancer Epidemiol 2015; 39: 388-93.
51. van Roon AH, Goede SL, van Ballegooijen M et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013; 62: 409-15.
52. Jensen CD, Corley DA, Quinn VP et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med 2016; 164: 456-63.
53. Federici A, Giorgi Rossi P, Borgia P et al. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen 2005; 12: 83-8.
54. Smith A, Young GP, Cole SR et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiacbased fecal occult blood test in detection of colorectal neoplasia. Cancer 2006; 107: 2152-9.
55. van Rossum LG, van Rijn AF, Laheij RJ et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90.
56. Hol L, van Leerdam ME, van Ballegooijen M et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59: 62-8.
57. Wong CK, Fedorak RN, Prosser CI et al. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis 2012; 27: 1657-64.
58. Chubak J, Bogart A, Fuller S et al. Uptake and positive predictive value of fecal occult blood tests: a randomized controlled trial. Prev Med 2013; 57: 671-8.
59. Hassan C, Giorgi Rossi P, Camilloni L et al. Metaanalysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 2012; 36: 929-40.
60. Raginel T, Puvinel J, Ferrand O et al. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Gastroenterology 2013; 144: 918-25.
61. Hol L, Wilschut JA, van Ballegooijen M et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-offlevels. Br J Cancer 2009; 100: 1103-10.
62. Vart G, Banzi R, Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med 2012; 55: 87-92.
63. Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut 2015; 64: 1327-37.
64. Robertson DJ, Imperiale TF. Stool testing for colorectal cancer screening. Gastroenterology 2015; 149: 1286-93.
65. Segnan N, Senore C, Andreoni B et al. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst 2005; 97: 347-57.
66. Segnan N, Senore C, Andreoni B et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology 2007; 132: 2304-12.
67. Khalid-de Bakker CA, Jonkers DM, Sanduleanu S et al. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res (Phila) 2011; 4: 1563-71.
68. Castells A, Quintero E, Alvarez C et al. Rate of detection of advanced neoplasms in proximal colon by simulated sigmoidoscopy vs fecal immunochemical tests. Clin Gastroenterol Hepatol 2014; 12: 1708-1716 e4.
69. Quintero E, Castells A, Bujanda L et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697-706.
70. CONFRIM trial. Available from http://www.clinicaltrials.gov/ct2/show/NCT01239082 Accessed: November 16, 2014.
71. Screesco trial. Available from http://www.clinicaltrials.gov/ct2/show/NCT02078804 Accessed: November 16, 2014.
72. Gupta S, Halm EA, Rockey DC et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Intern Med 2013; 173: 1725-32.
73. Hol L, Kuipers EJ, van Ballegooijen M et al. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer 2012; 130: 2096-102.
74. Senore C, Ederle A, Benazzato L et al. Offering people a choice for colorectal cancer screening. Gut 2013; 62: 735-40.
75. van Roon AH, Wilschut JA, Hol L et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 2011; 9: 333-9.
76. Wong MC, Ching JY, Chan VC et al. Diagnostic accuracy of a qualitative fecal immunochemical test varies with location of neoplasia but not number of specimens. Clin Gastroenterol Hepatol 2015; 13: 1472-9.
77. Guittet L, Bouvier V, Guillaume E et al. Colorectal cancer screening: why immunochemical faecal occult blood test performs as well with either one or two samples. Dig Liver Dis 2012; 44: 694-9.
78. Goede SL, van Roon AH, Reijerink JC et al. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2013; 62: 727-34.
79. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 659-69.
80. Day LW, Bhuket T, Allison J. FIT testing: an overview. Curr Gastroenterol Rep 2013; 15: 357.
81. Park MJ, Choi KS, Lee YK et al. A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program. Scand J Gastroenterol 2012; 47: 461-6.
82. Huang Y, Li Q, Ge W et al. Predictive power of quantitative and qualitative fecal immunochemical tests for hemoglobin in population screening for colorectal neoplasm. Eur J Cancer Prev 2014; 23: 27-34.
83. Tannous B, Lee-Lewandrowski E, Sharples C et al. Comparison of conventional guaiac to four immunochemical methods for fecal occult blood testing: implications for clinical practice in hospital and outpatient settings. Clin Chim Acta 2009; 400: 120-2.
84. Levy BT, Bay C, Xu Y et al. Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy. J Med Screen 2014; 21: 133-43.
85. Tao S, Seiler CM, Ronellenfitsch U et al. Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer. Acta Oncol 2013; 52: 1667-75.
86. Auge JM, Pellise M, Escudero JM et al. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program. Gastroenterology 2014; 147: 628-636 e1.
87. Wilschut JA, Hol L, Dekker E et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011; 141: 1648-1655 e1.
88. Cha JM, Lee JI, Joo KR et al. Use of a low cut-offvalue for the fecal immunochemical test enables better detection of proximal neoplasia. Dig Dis Sci 2013; 58: 3256-62.
89. Levin B, Lieberman DA, McFarland B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-95.
90. Plumb AA, Halligan S, Pendse DA et al. Sensitivity and specificity of CT colonography for the detection of colonic neoplasia after positive faecal occult blood testing: systematic review and meta-analysis. Eur Radiol 2014; 24: 1049-58.
91. Holleran G, Leen R, O'Morain C et al. Colon capsule endoscopy as possible filter test for colonoscopy selection in a screening population with positive fecal immunology. Endoscopy 2014; 46: 473-8.
92. Nakama H, Zhang B. Immunochemical fecal occult blood test is inadequate for screening test of stomach cancer. Dig Dis Sci 2000; 45: 2195-8.
93. Liu J, Finkelstein S, Francois F. Annual fecal occult blood testing can be safely suspended for up to 5 years after a negative colonoscopy in asymptomatic average-risk patients. Am J Gastroenterol 2015; 110: 1355-8.
94. Lieberman D, Nadel M, Smith RA et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc 2007; 65: 757-66.
95. Nadel MR, Berkowitz Z, Klabunde CN et al. Fecal occult blood testing beliefs and practices of U.S. primary care physicians: serious deviations from evidence-based recommendations. J Gen Intern Med 2010; 25: 833-9.
96. Winawer SJ, Zauber AG, Fletcher RH et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130: 1872-85.
97. Bampton PA, Sandford JJ, Cole SR et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut 2005; 54: 803-6.
98. Lane JM, Chow E, Young GP et al. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia. Gastroenterology 2010; 139: 1918-26.
99. Sawhney MS, McDougall H, Nelson DB et al. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 2010; 55: 1637-42.
100. Levi Z, Rozen P, Hazazi R et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 2009; 104: 933-8.
101. Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 2010; 304: 2513-20.
102. Mandelli G, Radaelli F, Paggi S et al. Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study. Eur J Gastroenterol Hepatol 2011; 23: 323-6.
103. Bujanda L, Lanas A, Quintero E et al. Effect of aspirin and antiplatelet drugs on the outcome of the fecal immunochemical test. Mayo Clin Proc 2013; 88: 683-9.
104. Bujanda L, Sarasqueta C, Lanas A et al. Effect of oral anticoagulants on the outcome of faecal immunochemical test. Br J Cancer 2014; 110: 1334-7.
105. Collins JF, Lieberman DA, Durbin TE et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005; 142: 81-5.
106. Nakama H, Zhang B, Abdul Fattah AS et al. Does stool collection method affect outcomes in immunochemical fecal occult blood testing? Dis Colon Rectum 2001; 44: 871-5.
107. Grazzini G, Ventura L, Zappa M et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 2010; 59: 1511-5.
108. van Roon AH, Hol L, van Vuuren AJ et al. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol 2012; 107: 99-107.
109. Cha JM, Lee JI, Joo KR et al. Performance of the fecal immunochemical test is not decreased by high ambient temperature in the rapid return system. Dig Dis Sci 2012; 57: 2178-83.
110. Chausserie S, Levillain R, Puvinel J et al. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening. Int J Cancer 2015; 136: 1827-34.
111. van Rossum LG, van Rijn AF, van Oijen MG et al. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer 2009; 125: 746-50.
112. Dancourt V, Hamza S, Manfredi S et al. Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colorectal cancer screening. Eur J Cancer Prev 2016; 25: 109-14.
113. Rex DK, Schoenfeld PS, Cohen J et al. Quality indicators for colonoscopy. Am J Gastroenterol 2015; 110: 72-90.
114. Chiu SY, Chuang SL, Chen SL et al. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program. Gut 2015, http://dx.doi.org/10.1136/gutjnl-2015-310256 [Epub ahead of print].
115. National Cancer Screening Service. Guidelines for quality assurance in colorectal cancer screening, 1st ed. Dublin, 2012, Available from http://www.cancerscreening.ie/publications/Guidelines-for-Quality-Assurancein-Colorectal-Screening.pdf Accessed: November 16, 2014.
116. Green BB, Wang CY, Anderson ML et al. An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. Ann Intern Med 2013; 158: 301-11.
117. Rabeneck L, Tinmouth JM, Paszat LF et al. Ontario's ColonCancerCheck: results from Canada's first province-wide colorectal cancer screening program. Cancer Epidemiol Biomarkers Prev 2014; 23: 508-15.
118. Logan RF, Patnick J, Nickerson C et al. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 2012; 61: 1439-46.
119. Malila N, Oivanen T, Malminiemi O et al. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ 2008; 337: a2261.
120. Chubak J, Garcia MP, Burnett-Hartman AN et al. Time to colonoscopy after positive fecal blood test in four U.S. health care systems. Cancer Epidemiol Biomarkers Prev 2016; 25: 344-50.